Company Profile

Cerevel Therapeutics Holdings Inc is a United States-based company. The Company is a clinical-stage biopharmaceutical company. The Company is focused on neuroscience that combines an understanding of disease-related biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) target receptor selective pharmacology to discover and design new therapies. It focuses on transform the lives of patients through the development of new therapies for neuroscience diseases, including schizophrenia, Alzheimerâ€™s disease psychosis, epilepsy, panic disorder and Parkinsonâ€™s disease.

Employees

355

Sector

Biotechnology & Medical Research

More about the company

24-08-04	Cerevel Therapeutics Holdings, Inc.(NasdaqCM:CERE) dropped from S&P Biotechnology Select Industry Index	CI
24-08-04	Cerevel Therapeutics Holdings, Inc.(NasdaqCM:CERE) dropped from S&P Global BMI Index	CI
24-08-04	Cerevel Therapeutics Holdings, Inc.(NasdaqCM:CERE) dropped from S&P TMI Index	CI
24-08-02	Analyst recommendations: Alphabet, Amazon, Lululemon, Intel, Qualcomm....
24-08-01	AbbVie Completes Acquisition of Cerevel Therapeutics	MT
24-08-01	AbbVie Completes Acquisition of Cerevel Therapeutics	MT
24-08-01	Cerevel Therapeutics Holdings, Inc. Announces Board Changes	CI
24-07-31	Cerevel Therapeutics Holdings, Inc.(NasdaqCM:CERE) dropped from NASDAQ Composite Index	CI
24-07-31	AbbVie Inc. completed the acquisition of Cerevel Therapeutics Holdings, Inc. from FMR LLC and others.	CI
24-06-30	Cerevel Therapeutics Holdings, Inc.(NasdaqCM:CERE) added to Russell 1000 Dynamic Index	CI
24-06-30	Cerevel Therapeutics Holdings, Inc.(NasdaqCM:CERE) added to Russell Midcap Growth Index	CI
24-06-30	Cerevel Therapeutics Holdings, Inc.(NasdaqCM:CERE) added to Russell 1000 Index	CI
24-06-30	Cerevel Therapeutics Holdings, Inc.(NasdaqCM:CERE) dropped from Russell 2000 Index	CI

24-08-02	Analyst recommendations: Alphabet, Amazon, Lululemon, Intel, Qualcomm....
24-02-15	Mizuho Raises Price Target on Cerevel Therapeutics to $45 From $25 to Reflect Sale Price to AbbVie, Keeps Neutral Rating	MT
23-12-28	JPMorgan Raises Price Target on Cerevel Therapeutics Holdings to $45 From $25, Keeps Neutral Rating	MT
23-12-22	Jefferies Downgrades Cerevel Therapeutics to Hold From Buy, Adjusts Price Target to $45 From $40	MT
23-12-08	TD Cowen Downgrades Cerevel Therapeutics to Market Perform From Outperform, Price Target is $45	MT

25-04-04	Entwistle & Cappucci LLP Files a Securities Class Action Against Cerevel Therapeutics Holdings, Inc., Bain Capital Investors, LLC and Pfizer, Inc.	BU
25-03-31	Entwistle & Cappucci LLP is Investigating Potential Federal Securities Law Violations in Connection with Cerevel Therapeutics Holdings, Inc. (CERE)	BU
24-08-01	AbbVie Completes Acquisition of Cerevel Therapeutics	PR
24-04-19	Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson's Disease	AQ
24-04-18	Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease	AQ

24-08-02	RECOMENDACIONES DE LOS ANALISTAS UK/EE.UU.: Alphabet, Amazon, Lululemon, Intel, Qualcomm....
24-02-22	USA-Les valeurs à suivre à Wall Street (actualisé)
24-02-02	Omzetdaling Abbvie valt mee
23-12-13	Pharma und Gesundheit: weitere Konsolidierung
23-12-12	Farma en gezondheid: consolidatie gaat door

3 years	21.86	44.99
5 years	19.59	46.16
10 years	9	46.16

Cerevel Therapeutics Holdings, Inc. Stock

Stocks

CERE

US15678U1280

Biotechnology & Medical Research

Latest news: Cerevel Therapeutics Holdings, Inc.

Analysts' recommendations: Cerevel Therapeutics Holdings, Inc.

Press Releases: Cerevel Therapeutics Holdings, Inc.

News in other languages: Cerevel Therapeutics Holdings, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Cerevel Therapeutics Holdings, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Company Profile

Manager	Title	Age	Since
John Renger CTO	Chief Tech/Sci/R&D Officer	57	2019-04-30
Matthew Calistri IRC	Investor Relations Contact	-	-
Paul Burgess PRN	Corporate Officer/Principal	53	2023-06-19

Date	Insider	Type	Main position	Quantity	% Market Cap.
8/1/24	Ramiro Sánchez	Issuer sale	Chief Medical Officer	1,495,399	0.8208%
8/1/24	Douglas Giordano	Issuer sale	Director	108,985	0.0598%
8/1/24	Marijn Dekkers	Issuer sale	Director	137,525	0.0755%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CEREVEL THERAPEUTICS HOLDINGS, INC.	+0.74%	-.--%	-	-	8.19B
WUXI APPTEC CO., LTD.	+0.79%	-6.16%	+49.32%	+74.50%	65.83B
LONZA GROUP AG	+1.92%	+10.35%	+13.02%	+87.74%	51.87B
ARGENX SE	+6.91%	+8.57%	+6.88%	+72.12%	51.2B
IQVIA HOLDINGS INC.	+0.74%	+2.75%	+26.31%	+45.29%	43.76B
BEONE MEDICINES AG	+3.87%	+10.15%	+20.69%	+132.73%	42.09B
REVOLUTION MEDICINES, INC.	+7.91%	+4.30%	+263.91%	+602.72%	39.04B
CELLTRION, INC.	-0.40%	+9.85%	+17.04%	+59.17%	34B
WUXI BIOLOGICS (CAYMAN) INC.	+1.00%	+1.73%	+40.48%	+9.64%	25.2B
GENMAB A/S	+2.36%	+5.34%	+30.98%	+26.07%	22.8B
Average	+2.59%	+1.67%	+52.07%	+123.33%	41.76B
Weighted average by Cap.	+2.82%	+2.01%	+50.31%	+125.32%